170 related articles for article (PubMed ID: 36409490)
1. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
[TBL] [Abstract][Full Text] [Related]
2. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
[TBL] [Abstract][Full Text] [Related]
3. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
Saberi Hosnijeh F; Kolijn PM; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Weiderpass E; Perduca V; Besson C; Mancini FR; Masala G; Krogh V; Ricceri F; Huerta JM; Petrova D; Sala N; Trichopoulou A; Karakatsani A; La Vecchia C; Kaaks R; Canzian F; Aune D; Boeing H; Schulze MB; Perez-Cornago A; Langerak AW; van der Velden VHJ; Vermeulen R
Sci Rep; 2020 Aug; 10(1):13814. PubMed ID: 32796953
[TBL] [Abstract][Full Text] [Related]
4. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
5. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
[No Abstract] [Full Text] [Related]
6. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
8. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
[TBL] [Abstract][Full Text] [Related]
9. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors.
Wang SS; Cozen W; Cerhan JR; Colt JS; Morton LM; Engels EA; Davis S; Severson RK; Rothman N; Chanock SJ; Hartge P
Cancer Res; 2007 May; 67(10):5042-54. PubMed ID: 17510437
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.
Charbonneau B; Maurer MJ; Ansell SM; Slager SL; Fredericksen ZS; Ziesmer SC; Macon WR; Habermann TM; Witzig TE; Link BK; Cerhan JR; Novak AJ
Cytokine; 2012 Dec; 60(3):882-9. PubMed ID: 23010502
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).
Epeldegui M; Lee JY; Martínez AC; Widney DP; Magpantay LI; Regidor D; Mitsuyasu R; Sparano JA; Ambinder RF; Martínez-Maza O
Clin Cancer Res; 2016 Jan; 22(2):328-36. PubMed ID: 26384320
[TBL] [Abstract][Full Text] [Related]
12. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
[TBL] [Abstract][Full Text] [Related]
13. Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival.
Nielsen KR; Steffensen R; Bendtsen MD; Rodrigo-Domingo M; Baech J; Haunstrup TM; Bergkvist KS; Schmitz A; Boedker JS; Johansen P; Dybkaeær K; Boeøgsted M; Johnsen HE
PLoS One; 2015; 10(10):e0139329. PubMed ID: 26448050
[TBL] [Abstract][Full Text] [Related]
14. Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis.
Späth F; Wibom C; Krop EJ; Johansson AS; Bergdahl IA; Vermeulen R; Melin B
Cancer Res; 2017 Mar; 77(6):1408-1415. PubMed ID: 28108506
[TBL] [Abstract][Full Text] [Related]
15. Expression of "DNA damage response" pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality.
Mansoor A; Kamran H; Rizwan H; Akhter A; Roshan TM; Shabani-Rad MT; Bavi P; Stewart D
Hematol Oncol; 2024 Jan; 42(1):e3225. PubMed ID: 37795760
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study.
Chang CM; Wang SS; Dave BJ; Jain S; Vasef MA; Weisenburger DD; Cozen W; Davis S; Severson RK; Lynch CF; Rothman N; Cerhan JR; Hartge P; Morton LM
Int J Cancer; 2011 Aug; 129(4):938-47. PubMed ID: 20949561
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of VEGF-A and Microvessel Density in Diffuse Large B-Cell Lymphoma and Low-Grade Follicular Lymphoma.
Shahini L; Gašparov S; Petruševska G; Manxhuka Kerliu S; Veselaj F; Kurshumliu F; Kavaja F
Acta Clin Croat; 2017 Dec; 56(4):588-593. PubMed ID: 29590710
[TBL] [Abstract][Full Text] [Related]
18. Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma.
Wu X; Pertovaara H; Korkola P; Dastidar P; Järvenpää R; Eskola H; Kellokumpu-Lehtinen PL
PLoS One; 2014; 9(1):e84999. PubMed ID: 24454777
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10
Azoulay D; Cohen HI; Dementiev E; Eshel E; Akria L; Shaoul E; Horowitz N
Cytometry B Clin Cytom; 2020 Sep; 98(5):449-453. PubMed ID: 31816181
[TBL] [Abstract][Full Text] [Related]
20. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
